Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia
-
- Klaus H. Metzeler
- Laboratory for Leukemia Diagnostics, Department of Internal Medicine III, Ludwig-Maximilans-Universität, Munich, Germany;
-
- Tobias Herold
- Laboratory for Leukemia Diagnostics, Department of Internal Medicine III, Ludwig-Maximilans-Universität, Munich, Germany;
-
- Maja Rothenberg-Thurley
- Laboratory for Leukemia Diagnostics, Department of Internal Medicine III, Ludwig-Maximilans-Universität, Munich, Germany;
-
- Susanne Amler
- Institute of Biostatistics and Clinical Research, University of Münster, Münster, Germany;
-
- Maria C. Sauerland
- Institute of Biostatistics and Clinical Research, University of Münster, Münster, Germany;
-
- Dennis Görlich
- Institute of Biostatistics and Clinical Research, University of Münster, Münster, Germany;
-
- Stephanie Schneider
- Laboratory for Leukemia Diagnostics, Department of Internal Medicine III, Ludwig-Maximilans-Universität, Munich, Germany;
-
- Nikola P. Konstandin
- Laboratory for Leukemia Diagnostics, Department of Internal Medicine III, Ludwig-Maximilans-Universität, Munich, Germany;
-
- Annika Dufour
- Laboratory for Leukemia Diagnostics, Department of Internal Medicine III, Ludwig-Maximilans-Universität, Munich, Germany;
-
- Kathrin Bräundl
- Laboratory for Leukemia Diagnostics, Department of Internal Medicine III, Ludwig-Maximilans-Universität, Munich, Germany;
-
- Bianka Ksienzyk
- Laboratory for Leukemia Diagnostics, Department of Internal Medicine III, Ludwig-Maximilans-Universität, Munich, Germany;
-
- Evelyn Zellmeier
- Laboratory for Leukemia Diagnostics, Department of Internal Medicine III, Ludwig-Maximilans-Universität, Munich, Germany;
-
- Luise Hartmann
- Laboratory for Leukemia Diagnostics, Department of Internal Medicine III, Ludwig-Maximilans-Universität, Munich, Germany;
-
- Philipp A. Greif
- Laboratory for Leukemia Diagnostics, Department of Internal Medicine III, Ludwig-Maximilans-Universität, Munich, Germany;
-
- Michael Fiegl
- Laboratory for Leukemia Diagnostics, Department of Internal Medicine III, Ludwig-Maximilans-Universität, Munich, Germany;
-
- Marion Subklewe
- Laboratory for Leukemia Diagnostics, Department of Internal Medicine III, Ludwig-Maximilans-Universität, Munich, Germany;
-
- Stefan K. Bohlander
- Department of Molecular Medicine and Pathology, University of Auckland, Auckland, New Zealand;
-
- Utz Krug
- Department of Internal Medicine 3, Klinikum Leverkusen, Leverkusen, Germany;
-
- Andreas Faldum
- Institute of Biostatistics and Clinical Research, University of Münster, Münster, Germany;
-
- Wolfgang E. Berdel
- Department of Medicine A, Hematology and Oncology, University of Münster, Münster, Germany;
-
- Bernhard Wörmann
- Department of Medicine, Hematology, Oncology, Tumor Immunology, Charité-Universitätsmedizin Berlin, Berlin, Germany; and
-
- Thomas Büchner
- Department of Medicine A, Hematology and Oncology, University of Münster, Münster, Germany;
-
- Wolfgang Hiddemann
- Laboratory for Leukemia Diagnostics, Department of Internal Medicine III, Ludwig-Maximilans-Universität, Munich, Germany;
-
- Jan Braess
- Department of Oncology and Hematology, Hospital Barmherzige Brüder, Regensburg, Germany
-
- Karsten Spiekermann
- Laboratory for Leukemia Diagnostics, Department of Internal Medicine III, Ludwig-Maximilans-Universität, Munich, Germany;
説明
<jats:title>Key Points</jats:title> <jats:p>We present comprehensive information on genetic driver events in a uniformly treated cohort of 664 adult AML patients aged 18 to 86 years. Mutations in NPM1, FLT3, CEBPA, TP53, and, in patients <60 years, DNMT3A and RUNX1, are the most important molecular risk factors in AML.</jats:p>
収録刊行物
-
- Blood
-
Blood 128 (5), 686-698, 2016-08-04
American Society of Hematology
